Cholestasis in preterm infants: when is a yellow alert? by Silvia, Nastasio & Giuseppe, Maggiore
MEETING ABSTRACT Open Access
Cholestasis in preterm infants: when is a yellow
alert?
Silvia Nastasio, Giuseppe Maggiore*
From XX National Congress of the Italian Society of Neonatology
Rome, Italy. 9-11 October 2014
Besides the transient bilirubin transport immaturity, pre-
term infants are particularly at risk for different forms
and degrees of bile formation impairment because of
metabolic demands that are not matched by functional
maturation in the first weeks of life.
Cholestasis, affecting approximately 1 of 2 500 infants,
is more commonly reported in preterm infants with an
incidence varying between 10 and 20%, and it is mainly
due to a combination of factors including delayed ent-
eral nutrition, low birth weight, prolonged parenteral
nutrition, hypoxia, infection, liver ischemia, immaturity
of bile acid metabolism, surgical procedures and multi-
ple drug treatments [1]. This reality of the setting is
defined as transient or multifactorial cholestasis [2],
which is the most frequent form of cholestasis in neona-
tal intensive care unit, usually transient and followed by
a gradual full recovery [3].
Cholestasis in preterm infants may however also be indi-
cative of a severe liver disease such as biliary atresia (BA)
or other biliary tract disorders. The development of a per-
sistent cholestatic jaundice, even in presence of colored
stools, incentives to conduct a thorough investigation [4].
Abdominal ultrasonography may support the diagnosis of
BA showing: absence of gallbladder, the “triangular cord”
sign or a cyst located at porta hepatis. Transient multifac-
torial cholestasis is a diagnosis of exclusion and a definitive
diagnosis can be made only after the complete resolution
of the clinical picture. Moreover, diagnosis of biliary atre-
sia in preterm jaundiced neonates is difficult since disco-
loration of stools can occur several weeks after birth [4].
Besides specific cholestatic disorders for which specific
medical and surgical treatment are available, there is no
unequivocal evidence that any medical treatment alters
the natural history of multifactorial cholestasis. Treatment
with ursodeoxycholic acid may indeed be useful, although
there is no evidence of effectiveness. Every effort must be
made to remove all risk factors for liver injury. Conse-
quences of cholestasis also need to be managed by admin-
istering fat -soluble vitamins, especially vitamin K and
nutritional formulas containing medium-chain fatty acids.
Although multifactorial transient cholestasis is the most
common cause of prolonged jaundice in preterm infants,
neonatologists need to be aware that premature infants
can also present with signs of severe liver disease. To
avoid any diagnostic delay it is mandatory to promptly
identify all the conditions suitable for an early and specific
treatment with a structured approach to the investigation
of cholestasis tailored to the preterm infant [5].
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